Accelerating R&D Investment in Core Areas and the Creation of New Drugs
First written in FY2016. 18 of 38 entries say "Advanced", first in FY2018-Q2. Latest entry: 2026-07-31.
2 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「The total R&D expenses of the Group during the interim consolidated accounting period were ¥16,328 million.」
Interim-period R&D expenses were ¥16,328 million, a substantial increase from ¥7,091 million in the same period of the previous year. R&D investment has expanded. - FY2025AdvancedAnnual report
「To achieve sustainable growth as a drug discovery-focused R&D company, we are further strengthening our drug discovery R&D structure focused on small molecules, advancing drug discovery projects rapidly and continuously to the clinical development stage, and expanding our product portfolio through licensing activities aligned with our therapeutic-area strategies. Total R&D expenses were ¥12,752 million.」
Under a policy of continuing small-molecule drug discovery and licensing activities, R&D expenses in the pharmaceutical business were ¥12,752 million, up from the previous fiscal year. - FY2025-H1AdvancedAnnual report
「The total R&D expenses of the Group during the interim consolidated accounting period were ¥7,091 million.」
R&D expenses increased from ¥4,499 million in the same period of the previous year to ¥7,091 million, expanding interim-period R&D investment. - FY2024Annual R&D expenses decreasedAnnual report
「To achieve sustainable growth as a drug discovery-focused R&D company, we are further strengthening our drug discovery R&D structure focused on small molecules, advancing drug discovery projects rapidly and continuously to the clinical development stage, and expanding our product portfolio through licensing activities aligned with our therapeutic-area strategies. Total R&D expenses were ¥9,323 million.」
While continuing small-molecule drug discovery and licensing activities, R&D expenses in the pharmaceutical business were ¥9,323 million and total Group R&D expenses were ¥9,474 million, both down from the previous fiscal year. - FY2024-Q2Decline in first-half research and development expensesAnnual report
「The total R&D expenses of the Group during the cumulative second quarter were ¥4,499 million.」
First-half R&D expenses were ¥4,499 million, down from ¥5,200 million in the same period of the previous year. R&D activities themselves have continued. - FY2024-Q1Quarterly R&D expenses decreasedAnnual report
「The total R&D expenses of the Group during the cumulative first quarter were ¥2,201 million.」
Quarterly R&D expenses were ¥2,201 million, down from ¥2,425 million in the same period of the previous year. R&D activities themselves have continued. - FY2023-Q3Decrease in third-quarter R&D expensesAnnual report
「The total R&D expenses of the Group during the cumulative third quarter were ¥7,643 million.」
R&D expenses for the cumulative third quarter were ¥7,643 million, down from ¥7,806 million in the same period of the previous year. - FY2023-Q2AdvancedAnnual report
「The total R&D expenses of the Group during the cumulative second quarter were ¥5,200 million.」
First-half R&D expenses were ¥5,200 million, up from ¥4,168 million in the same period of the previous year. A tangible increase is reflected in the amount of R&D investment. - FY2023-Q1AdvancedAnnual report
「The total R&D expenses of the Group during the cumulative first quarter were ¥2,425 million.」
First-quarter R&D expenses were ¥2,425 million, up from ¥2,392 million in the same period of the previous year. - FY2022AdvancedAnnual report
「To achieve sustainable growth as a drug discovery-focused R&D company, we are further strengthening our drug discovery R&D structure focused on small molecules, advancing drug discovery projects rapidly and continuously to the clinical development stage, and expanding our product portfolio through licensing activities aligned with our therapeutic-area strategies. Total R&D expenses were ¥10,239 million.」
The Group continues to strengthen its R&D structure focused on small molecules and pursue licensing activities. R&D expenses in the pharmaceutical business were ¥10,239 million, while total Group R&D expenses were ¥10,363 million. - FY2022-Q3AdvancedAnnual report
「The total R&D expenses of the Group during the cumulative third quarter were ¥7,806 million.」
R&D expenses for the cumulative third quarter were ¥7,806 million, up from ¥6,422 million in the same period of the previous year. - FY2022-Q2AdvancedAnnual report
「The total R&D expenses of the Group during the cumulative second quarter were ¥4,168 million.」
First-half R&D expenses were ¥4,168 million, up from ¥3,548 million in the same period of the previous year. The increase is reflected in investment in R&D activities. - FY2022-Q1Continued decrease in quarterly R&D expensesAnnual report
「The total R&D expenses of the Group during the cumulative first quarter were ¥2,189 million.」
Quarterly R&D expenses were ¥2,189 million, down from ¥2,392 million in the same period of the previous year. R&D activities themselves have continued. - FY2021-Q3Continued decrease in third-quarter R&D expensesAnnual report
「The total R&D expenses of the Group during the cumulative third quarter were ¥6,422 million.」
R&D expenses for the cumulative third quarter were ¥6,422 million, down from ¥8,053 million in the same period of the previous year. R&D activities themselves have continued. - FY2021-Q2Continued decrease in first-half R&D expensesAnnual report
「The total R&D expenses of the Group during the cumulative second quarter were ¥3,548 million.」
First-half R&D expenses were ¥3,548 million, down from ¥5,059 million in the same period of the previous year. R&D activities themselves have continued. - FY2021-Q1Quarterly R&D expenses decreasedAnnual report
「The total R&D expenses of the Group during the cumulative first quarter were ¥1,720 million. The changes by segment in the status of R&D activities during the cumulative first quarter are as follows. In the pharmaceutical business, we continue to advance R&D on each project and move projects to the next stage of development.」
While continuing R&D activities, quarterly R&D expenses were ¥1,720 million, down from ¥2,392 million in the same period of the previous year. - FY2020Decrease in annual R&D expenses and focus on small moleculesAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥10,767 million (equivalent to 17.0% of net sales). …In the pharmaceutical business, to achieve sustainable growth as a drug discovery-focused R&D company, we are further strengthening our drug discovery R&D structure focused on small molecules, advancing drug discovery projects rapidly and continuously to the clinical development stage, and expanding our product portfolio through licensing activities aligned with our therapeutic-area strategies.」
R&D expenses decreased from ¥15,711 million in the previous fiscal year to ¥10,767 million, or 17.0% of net sales, while the Group announced plans to strengthen its small-molecule-focused R&D structure and expand its portfolio through licensing activities. - FY2020-Q3Decrease in third-quarter R&D expensesAnnual report
「The total R&D expenses of the Group during the cumulative third quarter were ¥8,053 million.」
R&D expenses for the cumulative third quarter were ¥8,053 million, down from ¥12,428 million in the same period of the previous year. - FY2020-Q2Decline in first-half research and development expensesAnnual report
「The total R&D expenses of the Group during the cumulative second quarter were ¥5,059 million.」
R&D expenses for the first half were ¥5,059 million, down from ¥6,302 million in the same period of the previous year. The amount of R&D investment has changed. - FY2020-Q1RestatedAnnual report
「The total R&D expenses of the Group during the cumulative first quarter were ¥2,392 million.」
R&D expenses of ¥2,392 million were recorded for the quarter, and the Group continues to make R&D investments. - FY2019AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥15,711 million, equivalent to 21.7% of net sales.」
R&D expenses increased from ¥14,179 million in the previous fiscal year to ¥15,711 million, reaching 21.7% of net sales. - FY2019-Q3AdvancedAnnual report
「The total R&D expenses of the Group during the cumulative third quarter were ¥1,242.8 million.」
R&D expenses for the cumulative third quarter were ¥1,242.8 million, up from ¥1,104.5 million in the same period of the previous year. - FY2019-Q2Decline in first-half research and development expensesAnnual report
「The total R&D expenses of the Group during the cumulative second quarter were ¥630.2 million.」
R&D expenses were ¥630.2 million, down from ¥824.6 million in the same period of the previous year. The amount of R&D investment has changed. - FY2019-Q1RestatedAnnual report
「The total R&D expenses of the Group during the cumulative first quarter were ¥273.3 million. The changes by segment in the status of R&D activities during the cumulative first quarter are as follows.」
R&D expenses of ¥273.3 million were recorded for the quarter, and the Group continues to make R&D investments. - FY2018AdvancedAnnual report
「Total R&D expenses for the consolidated fiscal year were ¥1,417.9 million (equivalent to 19.2% of net sales).」
R&D expenses were ¥1,417.9 million, equivalent to 19.2% of net sales, up from ¥1,387.7 million in the previous fiscal year. - FY2018-Q3AdvancedAnnual report
「The total R&D expenses of the Group during the cumulative third quarter were ¥1,104.5 million.」
R&D expenses were ¥1,104.5 million, up from ¥983.4 million in the same period of the previous year. R&D investment has made tangible progress. - FY2018-Q2AdvancedAnnual report
「The total R&D expenses of the Group during the cumulative second quarter were ¥824.6 million.」
R&D expenses were ¥824.6 million, up from ¥648.1 million in the same period of the previous year, indicating progress in R&D investment. - FY2018-Q1RestatedAnnual report
「The total R&D expenses of the Group during the cumulative first quarter was ¥477.0 million. The changes by segment in the status of R&D activities during the cumulative first quarter are as follows.」
The Group invested ¥477.0 million in R&D during the quarter and continues to make R&D investments. - FY2017RestatedAnnual report
「In the pharmaceutical business, the core of the Group, we have defined core areas for R&D and are making proactive R&D investments to accelerate the creation and development of new drugs, with the aim of realizing our management vision of becoming a drug discovery-focused R&D company that develops and provides innovative pharmaceuticals contributing to the health of people worldwide. …Total R&D expenses for the consolidated fiscal year were ¥1,387.7 million, equivalent to 19.4% of net sales.」
The Group continues to invest in R&D in core areas to accelerate the creation and development of new drugs. Annual R&D expenses were ¥1,387.7 million, equivalent to 19.4% of net sales. - FY2017-Q3RestatedAnnual report
「The total R&D expenses of the Group during the cumulative third quarter was ¥983.4 million.」
The Group invested ¥983.4 million in R&D during the cumulative third quarter and continues to make R&D investments. - FY2017-Q2RestatedAnnual report
「The total R&D expenses of the Group during the cumulative second quarter was ¥648.1 million. We continue to advance R&D on each project and move projects to the next stage of development.」
R&D expenses were recorded, and the Group continues to advance each R&D project and move projects to the next stage of development. - FY2017-Q1RestatedAnnual report
「The total R&D expenses of the Group during the cumulative first quarter was ¥292.9 million. With regard to R&D activities, we continue to advance R&D on each project and move projects to the next stage of development.」
Quarterly R&D expenses were reported, with continued R&D on each project and continued advancement to the next stage of development. - FY2016First statedAnnual report
「In the pharmaceutical business, the core of the Group, we have defined core areas for R&D and are making proactive R&D investments to accelerate the creation and development of new drugs, with the aim of realizing our management vision of becoming a drug discovery-focused R&D company that develops and provides innovative pharmaceuticals contributing to the health of people worldwide.」
R&D expenses for the consolidated fiscal year were ¥1,410.6 million, equivalent to 19.8% of net sales.